- Home
- MANE vs FHI Comparison
MANE vs FHI Comparison
Compare MANE & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MANE | FHI |
|---|---|---|
| Founded | 2019 | 1955 |
| Country | United States | United States |
| Employees | 21 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.5B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | MANE | FHI |
|---|---|---|
| Price | $106.89 | $64.55 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | ★ $83.33 | $54.20 |
| AVG Volume (30 Days) | ★ 700.8K | 546.3K |
| Earning Date | 03-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.41% |
| EPS Growth | N/A | ★ 58.82 |
| EPS | N/A | ★ 2.65 |
| Revenue | N/A | ★ $1,102,924,000.00 |
| Revenue This Year | N/A | $9.90 |
| Revenue Next Year | N/A | $4.35 |
| P/E Ratio | ★ N/A | $24.13 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.26 | $46.66 |
| 52 Week High | $131.24 | $63.99 |
Technical Indicators
Market Signals| Indicator | MANE | FHI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 70.86 |
| Support Level | N/A | $51.79 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 1.29 |
| MACD | 0.00 | 0.55 |
| Stochastic Oscillator | 0.00 | 100.00 |
Price Performance
Historical ComparisonAbout MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
About FHI Federated Hermes Inc.
Federated Hermes provides asset management services for institutional and individual investors. The firm had $907.1 billion in managed assets at the end of the first quarter of 2026, composed of equity (11%), multi-asset (less than 1%), fixed-income (11%), alternative (2%), and money market (75%) funds. The company's cash management operations are expected to generate around 53% of Federated's revenue this year, compared with 30%, 10%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset/other operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (67% of AUM), institutional investors (26%), and international clients (7%).